Compare · CVRX vs DXCM
CVRX vs DXCM
Side-by-side comparison of CVRx Inc. (CVRX) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CVRX and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.10B, about 893.8x CVRX ($37.0M).
- Over the past year, CVRX is down 87.0% and DXCM is up 25.7% - DXCM leads by 112.7 points.
- DXCM has hit the wire 6 times in the past 4 weeks while CVRX has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 16 for CVRX).
- Company
- CVRx Inc.
- DexCom Inc.
- Price
- $1.31-5.42%
- $86.05-1.93%
- Market cap
- $37.0M
- $33.10B
- 1M return
- -56.48%
- -2.13%
- 1Y return
- -86.99%
- +25.75%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- 2005
- News (4w)
- 0
- 6
- Recent ratings
- 16
- 25
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest CVRX
- CVRx Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- CVRx Appoints John Landry as Chief Financial Officer
- CVRx Responds to Letter from Pointillist Family Office
- Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer
- CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy
- CHIEF OPERATING OFFICER Binkowski Brent bought $76,432 worth of shares (26,223 units at $2.91), increasing direct ownership by 87% to 56,514 units (SEC Form 4)
- CHIEF OPERATING OFFICER Binkowski Brent sold $3,338 worth of shares (1,309 units at $2.55), decreasing direct ownership by 4% to 30,291 units (SEC Form 4) (tax liability)
- CVRx Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- CVRx Announces Sales Leadership Transition
- CVRx, Inc. downgraded by Craig Hallum with a new price target
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer